Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Miguel Gil.
Pharmacoepidemiology and Drug Safety | 2016
Consuelo Huerta; Victoria Abbing-Karahagopian; Gema Requena; Belén Oliva; Yolanda Alvarez; Helga Gardarsdottir; Montserrat Miret; Cornelia Schneider; Miguel Gil; Patrick C. Souverein; Marie L. De Bruin; Jim Slattery; Mark C.H. De Groot; Ulrik Hesse; Marietta Rottenkolber; Sven Schmiedl; Dolores Montero; Andrew Bate; Ana Ruigómez; Luis A. García-Rodríguez; Saga Johansson; Frank de Vries; Raymond Schlienger; Robert Reynolds; Olaf H. Klungel; Francisco J. de Abajo
Studies on drug utilization usually do not allow direct cross‐national comparisons because of differences in the respective applied methods. This study aimed to compare time trends in BZDs prescribing by applying a common protocol and analyses plan in seven European electronic healthcare databases.
Journal of Thrombosis and Haemostasis | 2015
P. García-Poza; F. de Abajo; Miguel Gil; A. Chacón; V. Bryant; Luis A. García-Rodríguez
To assess the risk of non‐fatal ischemic stroke associated with non‐steroidal anti‐inflammatory drugs (NSAIDs) and paracetamol. The effects of dose, duration of treatment, background cardiovascular (CV) risk and use of concomitant aspirin were studied.
Pharmacoepidemiology and Drug Safety | 2014
Francisco J. de Abajo; Miguel Gil; Patricia García Poza; V. Bryant; Belén Oliva; Julia Timoner; Luis A. García-Rodríguez
The purpose of this study is to estimate the risk of nonfatal acute myocardial infarction (AMI) associated with traditional NSAIDs (tNSAIDs), non‐narcotic analgesics (paracetamol and metamizole), and symptomatic slow‐acting drugs in osteoarthritis (SYSADOAs) overall and in different subgroups of patients.
BMJ Open | 2013
Juan Erviti; Alvaro Alonso; Belén Oliva; Javier Gorricho; Antonio López; Julia Timoner; Consuelo Huerta; Miguel Gil; Francisco J. de Abajo
Objectives To evaluate the association between bisphosphonate use and the risk of atypical femoral fractures among women aged 65 or older. Design Nested case–control study. Setting General practice research database in Spain. Exposures Use of oral bisphosphonates before the occurrence of atypical fractures among cases or the corresponding index date among controls. Bisphosphonate use was categorised as ever versus never users. Ever users were divided according to the total time since first prescription. Main outcome measures Cases were defined as women aged 65 years or older with a first diagnosis of subtrochanteric or diaphyseal fracture, recorded in the BIFAP database between 1 January 2005 and 31 December 2008, and with at least 1 year of follow-up before the index date. For each case, five age-matched and calendar-year-matched controls without a history of hip or atypical fracture were randomly selected from the database. Statistical analysis OR of atypical femoral fracture by bisphosphonate use was determined using conditional logistic regression. Models were adjusted for comorbidities and use of other medications. Results The analysis included 44 cases and 220 matched controls (mean age, 82 years). Ever use of bisphosphonates was more frequent in cases than controls (29.6% vs 10.5%). In multivariate analyses, OR (95% CI) of atypical femoral fracture was 4.30 (1.55 to 11.9) in ever versus never users of bisphosphonates. The risk increased with long-term use, with an OR of 9.46 (2.17 to 41.3) comparing those using bisphosphonates over 3 years versus no users (p for trend=0.01). Conclusions Bisphosphonate use was associated with an increased risk of subtrochanteric or diaphyseal fractures in elderly women in a low fracture risk population, with a higher risk among long-term bisphosphonate users.
British Journal of Clinical Pharmacology | 2011
Miguel Gil; Belén Oliva; Julia Timoner; Miguel A. Maciá; V. Bryant; Francisco J. de Abajo
AIM Information from the spontaneous reporting system raised the hypothesis of an increased risk of meningioma in patients treated with high doses of cyproterone acetate (CPA). The objective of this study was to test the hypothesis of an increased risk of meningioma among users of high dose CPA as compared with non-users in a medical records computerized database. METHODS A retrospective cohort study was performed in a Spanish primary care database (BIFAP). Meningioma incidence rates were compared in patients exposed to high dose CPA (users) with those non-exposed and with those exposed to low dose CPA. Poisson regression analysis was used to estimate the incidence rate ratios after adjusting for age and gender. RESULTS Among 2474 users of high dose cyproterone (6663 person-years) four meningioma cases were identified, resulting in an incidence rate (IR) of 60.0 (95% CI 16.4, 153.7) per 100,000 person-years, which was significantly higher than that observed among the non-users (IR 6.6; 95% CI 6.0, 7.3) and among women users of low dose cyproterone (IR 0.0, 95% CI upper limit 5.5). After adjusting for age and gender, patients exposed to high dose CPA showed an increased risk of meningioma of 11.4 (95% CI 4.3, 30.8) as compared with non-users. CONCLUSIONS The results of this study support the hypothesis that the exposure to high dose CPA increases the risk of meningioma.
Epilepsia | 2014
Mark C.H. De Groot; Markus Schuerch; Frank de Vries; Ulrik Hesse; Belén Oliva; Miguel Gil; Consuelo Huerta; Gema Requena; Francisco J. de Abajo; Ana Afonso; Patrick C. Souverein; Yolanda Alvarez; Jim Slattery; Marietta Rottenkolber; Sven Schmiedl; Liset van Dijk; Raymond Schlienger; Robert Reynolds; Olaf H. Klungel
The annual prevalence of antiepileptic drug (AED) prescribing reported in the literature differs considerably among European countries due to use of different type of data sources, time periods, population distribution, and methodologic differences. This study aimed to measure prevalence of AED prescribing across seven European routine health care databases in Spain, Denmark, The Netherlands, the United Kingdom, and Germany using a standardized methodology and to investigate sources of variation.
Oncology | 2007
Anna Domènech; A. Benítez; M.T. Bajén; Maria Pla; Miguel Gil; J. Martín-Comín
Objective: To analyze the rate of axillary recurrences and survival in patients operated on for breast cancer who had not undergone an axillary lymph node dissection (ALND) because of a negative sentinel node biopsy. Methods: The study includes 97 patients operated on for breast cancer and selective node biopsy from June 2000 to December 2001 who had a negative sentinel node biopsy and did not undergo ALND. Mean age was 58.2 years (55.9–60.5). Follow-up was done up to 5 years. After surgery all patients underwent clinical examination. Complementary treatment depended on the hospital protocol. Rate of axillary recurrences, presence of distant metastases and survival (Kaplan-Meier method) were studied. Results: After a median follow-up of 4.1 years (2.18–5.25), only 2/95 patients (2.1%) developed distant metastases. Four patients died but only the death of the patient who presented multiple metastases was related to the primary breast cancer (1%). The 5-year overall survival rate was 96%. Conclusions: (1) Only 1/95 patients studied developed nodal extra-axillary recurrence together with distant metastases. (2) The results obtained support the selective sentinel node biopsy as an accurate technique in the axillary stratification of patients with breast cancer, offering in the cases of negative sentinel node biopsy a safe axillary control after a 5-year follow-up.
Pharmacoepidemiology and Drug Safety | 2016
Ruth Brauer; Ana Ruigómez; Gerry Downey; Andrew Bate; Luis A. García Rodríguez; Consuelo Huerta; Miguel Gil; Francisco J. de Abajo; Gema Requena; Yolanda Alvarez; Jim Slattery; Mark C.H. De Groot; Patrick C. Souverein; Ulrik Hesse; Marietta Rottenkolber; Sven Schmiedl; Frank de Vries; Maurille Feudjo Tepie; Raymond Schlienger; Liam Smeeth; Ian J. Douglas; Robert Reynolds; Olaf H. Klungel
There is widespread concern about increases in antibiotic use, but comparative data from different European countries on rates of use are lacking. This study was designed to measure and understand the variation in antibiotic utilization across five European countries.
BMC Research Notes | 2014
Josep Maria Escribà; Laura Pareja; Laura Esteban; Jordi Gálvez; Àngels Melià; Laura Roca; Ramon Clèries; Xavier Sanz; Montse Bustins; Maria Pla; Miguel Gil; Josep M. Borràs; Josepa Ribes
BackgroundBreast cancer (BC) is the most frequent cancer in women, accounting for 28% of all tumors among women in Catalonia (Spain). Mastectomy has been replaced over time by breast-conserving surgery (BCS) although not as rapidly as might be expected. The aim of this study was to assess the evolution of surgical procedures in incident BC cases in Catalonia between 2005 and 2011, and to analyze variations based on patient and hospital characteristics.MethodsWe processed data from the Catalonian Health Service’s Acute Hospital Discharge database (HDD) using ASEDAT software (Analysis, Selection and Extraction of Tumor Data) to identify all invasive BC incident cases according to the codes 174.0-174.9 of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) that were attended for the one-year periods in 2005, 2008 and 2011. Patients were classified according to surgical procedures (BCS vs mastectomy, and immediate vs delayed reconstruction), and results were compared among periods according to age, stage, comorbidity and hospital level.ResultsBC surgical procedures were performed in more than 80% of patients. Surgical cases showed a significant increasing trend in the proportion of women aged 50–69 years, more advanced disease stages, higher comorbidity and they were attended in hospitals of less complexity level throughout the study period. Similar pattern was found for patients treated with BCS, which increased significantly from 67.9% in 2005 to 74.0% in 2011.Simple lymph node removal increased significantly (from 48.8% to 71.4% and from 63.6% to 67.8% for 2005 and 2011 in conservative and radical surgery, respectively). A slightly increase in the proportion of mastectomized young women (from 28% in 2005 to 34% in 2011) was detected, due to multiple factors. About 22% of women underwent post-mastectomy breast reconstruction, this being mostly immediate.ConclusionsThe use of HDD linked to the ASEDAT allowed us to evaluate BC surgical treatment in Catalonia. A consolidating increasing trend of BCS was observed in women aged 50–69 years, which corresponds with the pattern in most European countries. Among the mastectomized patients, immediate breast reconstructions have risen significantly over the period 2005–2011.
Pharmacoepidemiology and Drug Safety | 2016
Patrick C. Souverein; Victoria Abbing-Karahagopian; E Martin; Consuelo Huerta; Francisco J. de Abajo; Hubert G. M. Leufkens; Gianmario Candore; Yolanda Alvarez; Jim Slattery; Montserrat Miret; Gema Requena; Miguel Gil; Rolf H.H. Groenwold; Robert Reynolds; Raymond Schlienger; John Logie; Mark C.H. De Groot; Olaf H. Klungel; Tjeerd van Staa; Toine C. G. Egberts; Marie L. De Bruin; Helga Gardarsdottir
Results from observational studies on the same exposure–outcome association may be inconsistent because of variations in methodological factors, clinical factors or health care systems. We evaluated the consistency of results assessing the association between antidepressant use and the risk of hip/femur fractures in three European primary care databases using two different study designs.